InsidersTradesSigma
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Browse the complete record of transactions filed by Newton Charles W.. Director active across 5 companies, notably Lyell Immunopharma, Inc.. Aggregated, 12 filings have been recorded. Breakdown: 1 buy · 2 sells. Total volume traded: €109k. History available since 9 February 2024. The latest transaction was disclosed on 18 August 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations
Newton Charles W. is a declarant associated with Lyell Immunopharma, Inc., where he is Chief Financial Officer, as well as 2seventy bio, Inc., Coherus Oncology, Inc., NOVAVAX INC and Keros Therapeutics, Inc., where he is Director. The record shows 11 filings in total, and among the recent filings available, the stated aggregate amounts are EUR 102580 of purchases and EUR 1187 of sales, over the period from 2024-02-13 to 2026-06-09.